6.40
+0.11
+(1.75%)
At close: April 17 at 4:00:01 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 5 | 4 |
| Avg. Estimate | 0 | 0 | -3.2 | -2.64 |
| Low Estimate | 0 | 0 | -3.39 | -3.25 |
| High Estimate | 0 | 0 | -2.86 | -2.15 |
| Year Ago EPS | -- | -- | -3.03 | -3.2 |
Revenue Estimate
| Currency in EUR | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 8 | 6 |
| Avg. Estimate | 3.11M | 3.11M | 7.24M | 5.87M |
| Low Estimate | 3.11M | 3.11M | -- | -- |
| High Estimate | 3.11M | 3.11M | 13M | 13.5M |
| Year Ago Sales | -- | -- | 12.5M | 7.24M |
| Sales Growth (year/est) | -- | -- | -42.06% | -18.89% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.79 | -0.79 | -0.67 | -0.7 |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | -3.2 | -2.64 |
| 7 Days Ago | 0 | 0 | -2.83 | -2.2 |
| 30 Days Ago | 0 | 0 | -2.74 | -2.14 |
| 60 Days Ago | 0 | 0 | -2.88 | -2.62 |
| 90 Days Ago | 0 | 0 | -2.94 | -2.58 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 2 |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | 4 | 2 |
| Down Last 30 Days | -- | -- | 4 | 4 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ABVX | -- | -- | -5.73% | 17.57% |
| S&P 500 | 7.04% | 5.20% | 8.89% | 14.14% |
Upgrades & Downgrades
| Reiterates | Citizens Capital Markets: Market Outperform to Market Outperform | 3/18/2025 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 1/10/2025 |
| Initiated | JMP Securities: Market Outperform | 12/4/2024 |
| Initiated | Laidlaw & Co.: Buy | 7/29/2024 |
| Initiated | BTIG: Buy | 5/20/2024 |
| Initiated | Guggenheim: Buy | 4/29/2024 |
Related Tickers
ALSEN.PA Sensorion SA
0.1700
-26.09%
MLYS Mineralys Therapeutics, Inc.
13.35
-1.11%
AVBP ArriVent BioPharma, Inc.
18.14
+1.34%
MAZE Maze Therapeutics, Inc.
8.41
+2.81%
MLTX MoonLake Immunotherapeutics
38.33
+3.67%
SYRE Spyre Therapeutics, Inc.
12.67
+2.01%
MRUS Merus N.V.
43.06
+2.73%
ELVN Enliven Therapeutics, Inc.
16.53
+2.86%
SION Sionna Therapeutics, Inc.
11.07
+10.70%
TRML Tourmaline Bio, Inc.
16.01
+10.26%